Detalles de la búsqueda
1.
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.
Arch Virol
; 165(7): 1633-1639, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32356185
2.
Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.
Arch Virol
; 169(3): 45, 2024 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38349452
Resultados
1 -
2
de 2
1
Próxima >
>>